Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07264426 · ClinicalTrials.gov registry record

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

A clinical trial of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, sponsored by argenx.

Recruiting
Registry status
200
Enrollment target
19
Study locations

NCT07264426: Recruiting study of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, sponsored by argenx.

NCT07264426 is a study of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy that is actively recruiting participants, run by argenx. The registered enrollment target is 200 participants, above the 150-participant average among 4 other CIDP trials with a reported enrollment target (33% higher). The trial reports 19 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07264426, a study of CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, is actively recruiting participants, sponsored by argenx.

RECRUITING
Registry status
200 participants
Enrollment target
19
Study locations

Study Summary

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Primary Outcome

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

Conditions Studied

CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Interventions

  • BIOLOGICAL Efgartigimod PH20 SC

Study Locations (19)

Other

  • Jüdisches Krankenhaus Berlin - Berlin
  • Universitätsklinikum Düsseldorf - Düsseldorf
  • Universitätsklinikum Frankfurt - Frankfurt
  • UKGM - Universitätsklinikum Gießen und Marburg GmbH - Giessen
  • Universitätsmedizin Göttingen - Göttingen
  • Universitätsklinikum Hamburg Eppendorf - Hamburg
  • Neurologie Neuer Wall - Dr.Bredow & Partner - Hamburg
  • Medizinische Hochschule Hannover - Hanover
  • Universitatsklinikum des Saarlandes - Homburg
  • Universitätsklinikum Magdeburg A.ö.R. - Magdeburg
  • Universitätsklinikum Mannheim - Mannheim
  • Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg - Marburg
  • Mühlenkreiskliniken - Johannes Wesling Klinikum Minden - Minden
  • Friedrich-Baur-Institute München - München
  • Immanuel Klinik Rüdersdorf - Rüdersdorf
  • Diakonie-Klinikum Schwäbisch Hall gGmbH - Schwäbisch Hall
  • Universitätsklinikum Tübingen - Tübingen
  • Universitätsklinikum Ulm - Ulm

North Carolina

  • PPD Virtual - Wilmington

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-08-11
Est. Completion 2029-10
argenx

49 total trials

What NCT07264426 shows while recruiting

NCT07264426 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 150-participant average among 4 other CIDP trials with a reported enrollment target (33% higher).

The record links to 3 conditions, with CIDP appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.

NCT07264426 lists 19 locations in 2 states (Other, North Carolina).

Frequently Asked Questions

What is clinical trial NCT07264426 about?

NCT07264426 is a clinical study titled "Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study". The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with...

What is the current status of trial NCT07264426?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-08-11. Estimated completion is 2029-10.

What conditions does trial NCT07264426 study?

This clinical trial studies the following conditions: CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy).

What interventions are being tested in trial NCT07264426?

The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).

Who is sponsoring clinical trial NCT07264426?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07264426 being conducted?

This trial has 19 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for CIDP

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07264426

Source: ClinicalTrials.gov NCT07264426, the US trial registry maintained by the National Library of Medicine. NCT07264426 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.